NCT02217488已完成1 期
Single Ascending Dose Tolerability Study of DG3173
Aspireo Pharmaceuticals Limited0 个研究点目标入组 72 人开始时间: 2008年5月最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 72
- 主要终点
- Number of serious adverse events or withdrawals due to adverse events
研究概览
简要总结
This clinical trial investigated the safety, tolerability and pharmacokinetic profile of DG3173 in a double-blind, randomized, placebo-controlled, single dose escalation Phase 1 study involving 72 healthy volunteers. Individuals received up to 2000 µg of DG3173 via single dose subcutaneous injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Ethnic origine: Caucasian
- •Weight: 55-95 kg
- •BMI: 19-29 kg/qm
- •Medical history without clinically relevant pathologies
- •Physical examination parameters and lung function without signs of clinically relevant pathologies
- •Electrocardiogram recording without signs of clinically relevant pathology, in particular QTc (Bazett) <440ms
- •Values for hematology, biochemistry and for coagulation tests of blood and urine within the normal range or showing no clinically relevant deviation as judged by the medical investigator (in particular normal values for ALAT, ASAT, LDH, gamma-GT, alkaline phosphatase, alpha-amylase and bilirubin)
- •Having given written informed consent before any study-related activities are carried out
排除标准
- •Evidence of clinically relevant pathology or disease
- •Any history of moderate or severe hypertension, hypotension or orthostatic hypotension
- •Mental handicap
- •Legal incapacity
- •Any history of clinically important emotional and/or psychiatric illness or of any clinically important neurological disorders and/or epilepsy
- •Chronic diarrhea or other chronic gastrointestinal disorders
- •Acute or chronic gastro-duodenal ulcers
- •Presence or history of endocrine disorders
- •Presence or history of gall stone disease, presence excluded by means of upper abdominal ultrasound
- •Known hypersensitivity to the study drug or constituent of the study drug
- •History of any relevant allergy, especially drug and/or food allergies
- •Strict vegetarian
- •Regular treatment with medications during three months prior to randomization
- •Receipt of any prescription or non-prescription medication, including multi-vitamin preparations within 14 days prior to drug administration and for the duration of the study
- •Use of St. John´s Wort or Ginkgo Biloba (also known as Ginkgo Bilbao) within 48 hours prior to randomization
- •Participation in a clinical study within 30 days prior to randomization
- •Donation of blood within 60 days prior to randomization
- •History of use of tobacco or nicotine-containing products within the past three months
- •Any history of alcohol abuse or drug addiction
- •Positive results at screen for drugs of abuse (cocaine, amphetamine/methamphetamine, tetrahydrocannbinol, opiates) or alcohol (breath test) at screening or on admission
- •Positive screen results for HBsAg, anti-HCV, or anti-HIV1&2
- •Consumption of abnormal quantities of coffee or tea (i.e. more than 5 cups per day [1 cup = 150 ml]
- •Any disease which in the Investigator´s opinion would exclude the subject from the study
研究组 & 干预措施
DG3173
Experimental
干预措施: DG3173 (Drug)
Vehicle
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of serious adverse events or withdrawals due to adverse events
时间窗: One week
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.AcromegalyNCT02235987Aspireo Pharmaceuticals Limited20
已完成
1 期
A Safety Study of LY3462817 in Healthy ParticipantsHealthyNCT03715192Eli Lilly and Company64
已完成
1 期
A Study of LY3200327 in Healthy ParticipantsHealthyNCT02595736Eli Lilly and Company52
已完成
1 期
Phase 1 Study of NGM313 in Healthy Adult ParticipantsObesityNCT02708576NGM Biopharmaceuticals, Inc151
已完成
1 期
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle GlaucomaGlaucoma, Open-AngleOcular HypertensionNCT01215786Allergan50